On May 26, 2022 Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, reported that President and CEO Athena Countouriotis, M.D., will participate in the Jefferies Healthcare Conference on June 8 and the 43rd Annual Goldman Sachs Healthcare Conference on June 14 (Press release, Turning Point Therapeutics, MAY 26, 2022, View Source [SID1234615188]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Countouriotis is scheduled to present a company overview in New York on June 8 at 11 a.m. ET and scheduled to participate in a fireside chat on June 14 in Rancho Palo Verdes, California at 1 p.m. ET.

Both sessions will be accessible via webcast through links that will be posted to the Investors page of www.tptherapeutics.com.